<DOC>
	<DOCNO>NCT00721058</DOCNO>
	<brief_summary>Rationale : Whole breast irradiation 50 Gy lumpectomy show reduce local recurrence rate factor 3 4 . An additional boost 16 Gy tumorbed show improve local control rate even . However , boost dose appear reduce local recurrence tumorbed , also elsewhere breast , suggest boost may always deliver correct region . In addition , even boost dose 16 Gy , local recurrence rate young patient still quite high - majority recurrence tumorbed . Consequently , improvement local control , especially young woman , still important aim pursue , order maintain breast conserve therapy ( BCT ) acceptable treatment option young woman . One way improve local control may increase dose [ Young Boost Trial ] , also improve definition tumorbed , i.e . target volume boost irradiation . Objective : The aim study investigate effect incorporate contrast-enhanced ( CE ) -CT-thorax target volume delineation process 1 ) coverage tumorbed 85 % isodose , 2 ) size irradiate boost volume , 3 ) interobserver variation target volume delineation . Study design : A CE-CT scan thorax make prior surgery , patient radiation treatment position . After breast conserving surgery , patient refer post-operative radiotherapy accord standard guideline . Prior radiotherapy , standard CT thorax scan make treatment planning . The planning target volume ( PTV ) boost delineate accord MAASTRO protocol , three independent observer ( PTV-1A-C ) , use plan CT . Delineation boost repeat 3D registration pre-operative CT scan plan CT-scan ( PTV-2A-C ) . Thereafter , consensus obtain PTV-1A-C PTV-2A-C , result one PTV-1 one PTV-2 patient . Radiation treatment plan ( RT-plans ) subsequently design PTV-1 PTV-2 . Coverage treatment plan 85 % isodose PTV-1- PTV-2 , irradiate volume ( percentage volume receive 95 % ( V95 ) ) calculate . Patients treat treatment plan PTV-2 . Study population : 60 breast cancer patient , treat BCT , mass visible mammography and/or ultrasound &gt; 0.5 cm , without contraindication CE-CT-thorax scan include . Intervention : &lt; 3 week prior lumpectomy CE-CT-thorax scan make entire thorax , patient position plan post-operative radiotherapy . Intravenous contrast give accord standard thorax protocol MAASTRO clinic . Main study parameters/endpoints : Primary endpoint : 1 . The percentage PTV-2 receiving &lt; 85 % dose , treat RT-plan PTV-1 . 2 . Difference V95 RT-plan design PTV-1- versus PTV-2 . Other endpoint interobserver variation , measure 1 ) percent volume overlap ; 2 ) difference standard deviation average PTV-1 PTV-2 ; 3 ) center mass assay . Nature extent burden risk associate participation , benefit group relatedness : Patients include write informed consent . The preoperative CE-CT-thorax-scan yield little additional radiation exposure , however negligible compare radiation treatment give breast cancer . In addition , small risk allergic reaction intravenous contrast , renal complication . Therefore , renal function check prior give contrast . A kreatinine clearance &lt; 60 ml/min contra-indication contrast . The pre-operative CT-scan make MAASTRO clinic , require additional visit MAASTRO clinic . A possible benefit may pre-operative CE-CT thorax may improve definition target volume , thereby reduce risk local recurrence .</brief_summary>
	<brief_title>Pre-operative Contrast Enhanced CT Improve Delineation Tumorbed Radiotherapy Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Eligible breast conserve therapy i.e . histologically proven breast cancer Operable disease Visible mass mammography ultrasound &gt; 0.5 c All contraindication breast conserve therapy , i.e . previous radiotherapy breast , multicentricity , inoperable disease , large tumor relatively small breast , pregnancy . Contraindications intravenous contrast , i.e . iodine allergy , renal malfunction ( kreatinine clearance &lt; 60 ml/min ) , , previous allergic reaction i.v . contrast , M. Kahler , use NSAIDs , Diuretics Metformine . Absence tumor mass &gt; 0.5 cm conventional mammography ultrasound</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Eligible</keyword>
	<keyword>Operable</keyword>
	<keyword>Disease</keyword>
	<keyword>Conserving</keyword>
	<keyword>Therapy</keyword>
	<keyword>Visible mass mammography</keyword>
	<keyword>Ultrasound &gt; 0.5 cm</keyword>
	<keyword>Histologically</keyword>
	<keyword>Proven</keyword>
</DOC>